Hamilton Wealth LLC Buys New Stake in Novartis AG $NVS

Hamilton Wealth LLC bought a new position in Novartis AG (NYSE:NVS) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,660 shares of the company’s stock, valued at approximately $559,000.

Several other hedge funds have also recently bought and sold shares of the stock. Auto Owners Insurance Co boosted its stake in shares of Novartis by 13,687.0% in the 4th quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock valued at $638,103,000 after purchasing an additional 4,594,726 shares in the last quarter. WCM Investment Management LLC bought a new stake in Novartis during the first quarter worth about $220,004,000. Morgan Stanley raised its stake in shares of Novartis by 14.9% in the fourth quarter. Morgan Stanley now owns 8,876,906 shares of the company’s stock valued at $1,223,860,000 after acquiring an additional 1,148,033 shares during the last quarter. GQG Partners LLC boosted its holdings in shares of Novartis by 39.6% in the 4th quarter. GQG Partners LLC now owns 3,158,122 shares of the company’s stock worth $435,414,000 after acquiring an additional 895,255 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Novartis during the 4th quarter worth approximately $108,638,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Stock Performance

NVS stock opened at $158.82 on Thursday. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. The company has a 50 day moving average price of $152.44 and a 200 day moving average price of $152.58. Novartis AG has a fifty-two week low of $112.34 and a fifty-two week high of $170.46. The stock has a market capitalization of $303.06 billion, a PE ratio of 23.96, a price-to-earnings-growth ratio of 2.75 and a beta of 0.45.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The firm had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. Analysts forecast that Novartis AG will post 8.8 EPS for the current year.

Analyst Ratings Changes

NVS has been the subject of several research analyst reports. Citigroup reiterated a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $141.20.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.